EGFR Inhibitors: Managing Skin Rash and Nail Inflammation (Paronychia), a Patient Guide
In this article
EGFR inhibitors (tablets such as osimertinib, afatinib, gefitinib and erlotinib, and antibodies such as amivantamab) block the EGFR pathway in cancer cells but also affect EGFR in healthy skin cells; as a result, most people on treatment develop an acne-like rash on the face, scalp and upper trunk, dry skin and inflammation around the nails (paronychia). This is not an allergy and is often not an infection either; it is a side effect to be managed while the drug continues. Frequency varies widely with the drug: according to the sources, severe (grade 3 or higher) rash is around 1% with osimertinib and 16–17% with afatinib and with amivantamab plus lazertinib. Regular moisturizing, sun protection and, when your doctor agrees, preventive antibiotics may reduce the problem. This article is not for treating yourself, but for knowing what to report, when and to whom: do not stop the drug or change the dose on your own, and tell your oncology team early about changes in your skin and nails.
Who is this article for? Patients with lung and other cancers who take or are about to start an EGFR inhibitor, and their relatives, people who have a rash or nail inflammation, and health professionals interested in the topic. This article is not medical advice; no diagnosis should be made, no drug started, no dose changed and no treatment already started stopped on the basis of this text. Only the doctors who follow you can assess what applies to you.
Do EGFR inhibitors cause skin and nail problems?
Yes. According to the summary from eviQ in Australia, an acne-like (papulopustular) rash is the most common skin reaction to EGFR inhibitors and results directly from blocking EGFR; it is not an allergic reaction. The rash is usually sterile, that is, not caused by bacteria, although secondary infection can be added later. It appears mainly where oil glands are dense, that is, on the face (nose, cheeks, forehead, chin), scalp, shoulders and upper trunk; the palms, soles and mucous membranes are usually spared.
| Drugs involved | Tablets (osimertinib, afatinib, gefitinib, erlotinib, lapatinib) and antibodies (cetuximab, panitumumab, amivantamab); antibodies usually cause a more frequent and more marked rash |
| Appearance of the rash | Red bumps and pimples on the face, scalp and upper trunk; itching, tenderness and dryness may accompany it |
| Timing | According to the eviQ summary, in about 85% of patients, mostly within the first 4 weeks; severe skin toxicity 5–10% |
| Phases | Week 1 redness and sensory change, weeks 1–3 bumps and pimples, weeks 3–5 crusting, weeks 5–8 visible small blood vessels |
| Nail-fold inflammation | Usually appears after the rash, within weeks; with amivantamab alone, median onset is about 68.5 days |
| Why does it happen? | Not an allergy, but blockade of EGFR in skin and nail cells |
This information rests on two different sources: the eviQ summary was written mainly for cetuximab, panitumumab, gefitinib, erlotinib and lapatinib; the median onset times come from the CHRYSALIS study of amivantamab given alone, as reported on the manufacturer’s page. The same timing does not apply to every patient and every drug.
How common is it and how does it differ by drug?
Skin and nail side effects do not occur with the same frequency with every EGFR inhibitor. The table below brings together study data from the prescribing information and the manufacturer’s medical information page. Because they come from different studies, they give a rough idea rather than a direct comparison:
| Drug (study) | Rash | Paronychia or nail | Dry skin |
|---|---|---|---|
| Osimertinib (FLAURA, 279 patients) | 58% (1.1%) | Nail toxicity 35% (0.4%) | 36% (0.4%) |
| Gefitinib or erlotinib (FLAURA comparator arm, 277 patients) | 78% (7%) | Nail toxicity 33% (0.7%) | 36% (1.1%) |
| Afatinib (LUX-Lung 3, 229 patients) | Rash or acneiform dermatitis 90% (16%) | Paronychia 58% (11%) | 31% (0%) |
| Amivantamab + lazertinib (MARIPOSA, 421 patients) | Rash 64% (17%); acneiform dermatitis 30% (9%) | Paronychia 69% (12%) | 17% (under 1%) |
Rates of severe rash
Grade 3 or higher rash (%)
First-line EGFR inhibitor studies; prescribing information and manufacturer data.
Bar lengths are drawn relative to the highest value. For afatinib the value is reported together as “rash or acneiform dermatitis.”
Short answer: which drug causes the most trouble?
- In these data, the least severe rash is reported with osimertinib (1.1% in FLAURA; 7% with gefitinib or erlotinib in the same study).
- With afatinib, both rash (90%) and paronychia (58%) are very common, and grade 3 rash is 16%.
- With amivantamab plus lazertinib, paronychia (69%) and severe rash (17%) are among the highest rates; for this reason a separate preventive skin program was developed for this combination.
Limits of the comparison. The table comes from studies run in different patient groups, in different periods and with different terms; “rash,” “acneiform dermatitis” and “nail toxicity” do not measure the same thing. Do not read these figures as a one-to-one comparison. The source we used for osimertinib reports “nail toxicity” rather than “paronychia”; we could not reach the skin data of the osimertinib arm in the MARIPOSA study. The figures are taken from prescribing information and the manufacturer’s page, not from an independent review.
What are the symptoms and when do they start?
Symptoms begin in the first weeks after the drug starts and change over time. The sources list the following:
- Red bumps and inflamed pimples on the face, scalp, neck and upper trunk (acne-like rash)
- Tenderness, burning, stinging or itching of the skin
- Dry, flaking and cracking skin; fissures especially on fingertips and heels
- Redness, crusting and pain of the scalp
- Redness, swelling and pain at the nail edges, with oozing around them
- Over time, raised, easily bleeding flesh-like tissue at the nail edge (pyogenic granuloma-like lesion)
Rash and nail problems can start mild in the first days and increase over weeks. According to the eviQ summary, redness and dryness can persist after the rash has settled.
When should you reach your oncology team without waiting?
- If the rash is spreading, becoming painful or limiting daily activities (dressing, washing hands, walking).
- If your skin or nail area shows signs of infection such as pus, increasing warmth, rapidly spreading redness or fever.
- If there is blistering, peeling, bruising or dark, damaged-looking tissue on the skin; eviQ recommends referral to a dermatologist in these situations.
Prevention: daily skin care and preventive treatment
The shared message of the sources is to start skin care from the first day of the drug and to tell the team at the first sign. eviQ and the drug manufacturer’s page list the following daily measures:
- Moisturizing: Apply an alcohol-free, thick moisturizer at least twice a day; creams and ointments are preferred over lotions and gels.
- Sun protection: Avoid the sun, use protective clothing and a hat, and apply a broad-spectrum sunscreen of SPF 30 or higher containing titanium dioxide or zinc oxide (eviQ recommends SPF 50 or higher). Do not apply sunscreen to the radiotherapy field.
- Avoiding heat: Steam, saunas, hot baths, heating pads and vigorous exercise can trigger the rash; take short, lukewarm showers and use bath oil instead of soap or shower gel.
- Avoiding the wrong products: Over-the-counter acne products (retinoids, benzoyl peroxide), topical anesthetics, diphenhydramine creams and antibacterial, alcohol-based or perfumed products can dry or irritate the skin further. Alcohol-based gels and hand sanitizers also increase dryness.
- Nails: Reduce pressure and friction on the fingertips and nail edges; avoid tight shoes.
The evidence for preventive treatment comes from the following studies. In the STEPP study with panitumumab (an antibody), a preventive program that started a day before the drug and lasted 6 weeks (moisturizer, sunscreen, 1% hydrocortisone cream at bedtime and doxycycline 100 mg twice daily) was compared with treatment started once the rash appeared; grade 2 skin toxicity was 29% versus 62% (eviQ summary). That study was done in patients with colorectal cancer; it does not apply directly to the tablets used in lung cancer. For amivantamab with lazertinib, the manufacturer states that preventive antibiotics (cream or tablet) should be strongly considered for the first 8 weeks, with backup prescriptions ready from the start.
The COCOON study: a preventive program for people taking amivantamab with lazertinib
COCOON is a randomized, open-label phase 2 study in patients with lung cancer carrying an EGFR change who received amivantamab with lazertinib as first-line treatment. The interim analysis evaluated 138 patients (70 in the preventive program, 68 on standard care; the study as a whole is reported to include 201 patients). The preventive program consisted of doxycycline or minocycline 100 mg twice daily for 12 weeks, 1% clindamycin to the scalp, 4% chlorhexidine wash for the hands and feet, and a ceramide-based daily moisturizer. Grade 2 or higher skin side effects in the first 12 weeks were 38.6% versus 76.5% (odds ratio 0.19; 95% confidence interval 0.09–0.40). Drug interruption was reported as 16% versus 34%, and dose reduction as 7% versus 19%.
Limits of the evidence. The COCOON data are an interim analysis presented at a congress (ELCC 2025); in the sources we could reach, there is no peer-reviewed full publication. The study is open-label, meaning patient and doctor know which arm they are in; the sponsor is the drug company; the content of the “standard care” arm is not described in detail. In these sources rash and paronychia are not reported separately; although the rate of patients reporting no nail infection symptoms was 27% versus 16%, the difference was not significant (p=0.270). So these data do not show that the program alone reduces paronychia. Your doctor decides the dose and the drug choice.
How is the rash managed if it appears?
The approach doctors use depends on the severity of the rash. A summary of the regimen suggested by eviQ is below; it is a source for doctors and not a plan for patients to apply on their own:
| Grade | Definition | Commonly suggested approach |
|---|---|---|
| Grade 1 | Under 10% of body surface; itching or tenderness may be present | Drug dose is not reduced; hydrocortisone 1–2.5% cream and/or clindamycin 1% gel or metronidazole 0.75% cream twice daily; doxycycline or minocycline 100 mg twice daily may be considered; reassessment after 2 weeks |
| Grade 2 | 10–30% of body surface or psychosocial impact | No dose reduction; in addition to topical treatment, doxycycline or minocycline 100 mg twice daily for at least 4 weeks and throughout treatment; regular pain relief if there is pain; reassessment after 2 weeks |
| Grade 3–4 | More than 30% of body surface with moderate to severe symptoms, limitation of self-care, or infection needing antibiotics | Drug dose is reduced; if there is pus, a culture is taken before choosing an antibiotic; saline compresses 2–3 times a day may be considered; if it does not settle, the drug is interrupted; dermatology assessment |
eviQ suggests avoiding a topical corticosteroid combined with an antibiotic in grade 3–4 rash, because this combination may prolong the late-phase rash. For amivantamab with lazertinib, the manufacturer states that a dermatology opinion should be sought if grade 2 rash does not improve within 2 weeks, becomes grade 3 or looks atypical.
How is paronychia (nail-fold inflammation) managed?
Paronychia is redness, swelling and pain in the side and back folds of the nail; over time, raised granulation tissue that bleeds easily can develop there. The patient often notices only the fingernails; experts stress that the toenails also need to be examined separately. The approach in the sources is stepwise:
- Step 1, antiseptic soaks: Lukewarm soaks with diluted bleach, iodine compounds or white vinegar help prevent superinfection and are intensified if infection develops (ESMO page, written for multikinase inhibitors; the OncLive experts also name warm water and vinegar soaks). Your doctor tells you which mixture and frequency suit you.
- Step 2, potent topical steroid: First-line treatment is high-potency topical corticosteroids; calcineurin inhibitors are an alternative. Tetracycline-group antibiotics are used to reduce inflammation.
- Step 3, antibiotics only when needed: Antimicrobial drugs are given for culture-proven infection; for this reason the doctor may want to take a culture before choosing a drug.
- Step 4, raised tissue (granuloma-like lesion): Electrocautery or silver nitrate cauterization can be applied; if these are not enough, removal of the nail plate is considered. Weekly review is recommended.
- Support: Input from a dermatologist and a podiatrist can be helpful. In a small case series (9 patients), 0.5% timolol gel applied twice daily gave a complete response in 13 of 25 lesions; this evidence is limited and is not a routine recommendation.
Experts state that for grade 2 or higher paronychia, dose reduction or temporary interruption of the EGFR inhibitor is considered. Having patients send photos of their skin and nails to the team can make follow-up easier without coming to the hospital.
Six common misunderstandings:
- “The rash means I am allergic to the drug.” No. The rash comes from blocking EGFR in skin cells; it is not an allergic reaction.
- “It looks like a pimple, so I will put acne cream on it.” No. Over-the-counter acne products (retinoids, benzoyl peroxide) dry and irritate the skin further.
- “If there is a rash, I should stop the drug myself.” No. Changing the dose or stopping the drug is the doctor’s decision; in most cases the skin is treated while the drug continues.
- “Nail-fold inflammation is a small problem; I will wait.” No. If untreated, painful, bleeding raised tissue can develop and limit daily life.
- “If I stay in the sun, the rash will dry up by itself.” No. The sun can worsen the rash; sun protection is recommended.
- “Skin side effects are the same with all EGFR inhibitors.” No. In these data, severe rash is about 1.1% with osimertinib and 16–17% with afatinib and with amivantamab plus lazertinib.
When is the drug dose reduced or the drug paused?
If the skin side effect cannot be brought under control, doctors may pause the drug temporarily or reduce the dose; the aim is to be able to continue the drug safely for a long time. These decisions differ by drug:
- Afatinib: The drug is withheld for a prolonged (more than 7 days) or intolerable grade 2 skin reaction; when it settles, it is restarted at a daily dose 10 mg lower. It is stopped permanently for life-threatening blistering, bullous or exfoliating skin lesions.
- Amivantamab with lazertinib: In grade 3 rash, amivantamab is withheld until it falls to grade 2 or lower; in grade 4 rash, lazertinib is withheld temporarily and amivantamab is stopped permanently; in severe blistering or peeling conditions, amivantamab is stopped permanently.
- General rule: In grade 1 rash the dose mostly stays the same and is reassessed after 2 weeks.
This information is taken from prescribing information and manufacturer pages; the plan that applies to you is your doctor’s decision.
Questions you can ask your oncologist
If you take or are about to start an EGFR inhibitor, you can ask:
- How often do skin and nail side effects occur with the drug I will take, and in which weeks should I expect them to start?
- Is a preventive skin care program or preventive antibiotic suitable for me? Which products should I use and which should I avoid?
- If a rash or nail problem starts, whom should I tell, at which phone number and how quickly?
- Which symptoms call for stopping the drug immediately or for urgent assessment?
- How would my drug dose be changed in a severe rash; can I restart the drug?
- Do I need to be referred to a dermatologist or a podiatrist?
- Are there specific products you recommend for sunscreen, moisturizer and nail care?
The situation in Türkiye. For this article we did not check access to the drugs in Türkiye, reimbursement conditions, access to dermatology and podiatry services, or whether COCOON-like preventive programs are applied; we made no assumptions on these points. For detecting an EGFR change, see our article on next-generation sequencing (NGS), and for the availability of new drugs in Türkiye, our article on the access map for newly FDA-approved cancer drugs (both in Turkish).
DROZDOGAN Academy Commentary
The skin and nail side effects of EGFR inhibitors are not a coincidence but a consequence of the drug’s mechanism; so the best management is to discuss what to expect before the drug starts and to tell the team at the first sign. The most important practical point for patients is to see the side effect not as a reason to give up treatment but as a manageable problem.
⚡ Why it matters
Because skin and nail side effects are visible and painful, they affect daily life, sleep and social life; when severe, they can lead to dose reduction or interruption. Early and correct management may help keep the drug going at the planned dose. This assessment is ours.
✅ What is well supported
That the rash is a direct result of EGFR blockade and not an allergy, and that its frequency changes markedly with the drug, is consistent across prescribing information and several sources. Basic measures such as moisturizing, sun protection and avoiding heat triggers are shared by eviQ and the manufacturer’s page.
⚠️ What is weakly supported
COCOON is an interim analysis, presented at a congress, open-label and sponsor-supported, without a full publication; paronychia is not reported separately. STEPP was done with an antibody and in colorectal cancer. For paronychia treatment the figures are mostly small series and expert opinion; the ESMO page is for multikinase inhibitors.
🩺 Practical meaning for patient and doctor
Before the drug starts, the products to be used, the emergency phone number and photo sharing should be discussed. If rash and nail symptoms are reported early, they are usually managed stepwise; dose change is the doctor’s decision. If there is fever, pus, widespread blistering or peeling, seek care without waiting.
❓ Open questions
Whether preventive antibiotic programs really reduce paronychia, whether preventive treatment is needed for drugs that cause less rash such as osimertinib, and the best duration are not answered in the sources of this article.
Conclusion: Acne-like rash, dry skin and nail-fold inflammation with EGFR inhibitors are mechanism-related side effects whose frequency varies with the drug and which are manageable in most patients. Daily moisturizing and sun protection, preventive antibiotics when appropriate and stepwise treatment are the basic approach. If you notice changes in your skin or nails, tell your oncology team early without stopping the drug on your own; if there is fever, pus, widespread blistering or peeling, seek care without waiting.
Frequently asked questions
- Why do EGFR inhibitors cause a skin rash?
- EGFR is found not only in cancer cells but also in skin and nail cells. When the drug blocks this pathway, an inflamed, acne-like rash develops on the skin. This is not an allergy.
- When does the rash start and how long does it last?
- According to the eviQ summary, it mostly starts in the first 4 weeks; the bump phase is seen in weeks 1–3 and crusting in weeks 3–5. Redness and dryness can persist after the rash has gone. The duration varies with the person and the drug.
- I take osimertinib; will I have skin problems?
- In the FLAURA data, rash with osimertinib was 58%, dry skin 36% and nail toxicity 35%; severe (grade 3 or higher) rash is 1.1%. So the side effect can be common but is mostly mild.
- What should I do about nail-fold inflammation?
- Tell your doctor early. The sources mention antiseptic soaks, a potent topical steroid and, if needed, antibiotics; if there is raised tissue, procedures such as cauterization may be needed. Do not try your own mixtures at home without asking your doctor.
- Are preventive antibiotics necessary for everyone?
- No. In combinations with frequent skin side effects such as amivantamab with lazertinib, preventive antibiotics are considered in the first weeks; for other drugs the doctor decides case by case.
- What should I look for when choosing sunscreen and moisturizer?
- An alcohol-free, thick moisturizer and a broad-spectrum sunscreen of SPF 30 or higher are recommended; those containing titanium dioxide or zinc oxide are preferred. Avoid perfumed and alcohol-based products.
- Do I need to stop the drug?
- In most cases, no. If the side effect is severe, the doctor may reduce the dose or pause the drug temporarily. The decision to stop or change the dose belongs to the doctor; do not change it on your own.
Glossary
- EGFR
- Epidermal growth factor receptor; a surface protein that directs cell growth, found in cancer cells and in skin cells.
- EGFR inhibitor
- A drug that blocks the EGFR pathway; it can be a tablet (osimertinib, afatinib) or an antibody (amivantamab, cetuximab).
- Acneiform (papulopustular) rash
- A rash of bumps and inflamed pimples that resembles acne but is not caused by bacteria.
- Paronychia
- Inflammation of the side and back folds of the nail with redness, swelling and pain.
- Pyogenic granuloma-like lesion
- Raised, easily bleeding granulation tissue that develops at the nail edge.
- Grade (CTCAE)
- The standard system that grades the severity of a side effect from 1 to 4.
- Emollient (moisturizer)
- A cream or ointment that softens the skin and reduces water loss.
- Antiseptic soak
- A soak in diluted antiseptic or vinegar water to reduce germs.
- Preventive (proactive) treatment
- Treatment started together with the drug before the side effect appears.
- Randomized open-label study
- A study in which patients are randomly assigned to groups but the patient and doctor know which treatment is received.
Transparency note. Verified: definition, timing and grading of acne-like rash, daily care recommendations, the STEPP summary and management by grade (eviQ summary page; the page shows conflicting review dates, so its current version should be confirmed on the eviQ site before clinical use); osimertinib and gefitinib/erlotinib data (Tagrisso prescribing information, FLAURA table); afatinib data (Gilotrif prescribing information, LUX-Lung 3 table); amivantamab with lazertinib data, prevention and dose changes (manufacturer’s medical information page, MARIPOSA final overall survival analysis); the COCOON study (manufacturer’s press release, CURE and CancerNetwork reports, ILCN interview; ELCC 2025 interim analysis); the design of the MARIPOSA study (ASCO Post summary, NEJM publication); for paronychia, the ESMO page, the OncLive expert opinion and the case series by Sollena et al. 2019. Secondary citation only: the grade table on the ESMO page was blank and the page is for multikinase inhibitors; we could not access the full text of the MASCC guideline, the NCCN and ESMO guidelines, or the original FLAURA, LUX-Lung 3 and MARIPOSA papers (PubMed and NEJM access was blocked). Not written because unverified: a paronychia-specific rate for osimertinib (the prescribing information reports “nail toxicity”); separate rash and paronychia results in COCOON; current Turkish prescribing details of the drugs; access and reimbursement in Türkiye; overlap with existing articles on drozdogan.com (not checked). Small inconsistencies: the rate of grade 2 or higher in COCOON is rounded differently by source, 38.6%/76.5% (CURE, a news site) versus 39%/77% (company release); we used the figures of the first two sources. For sunscreen, eviQ recommends SPF 50 or higher and the manufacturer SPF 30 or higher. Assessments and comments belong to this article. This article is not medical advice; no diagnosis should be made, no treatment decision taken and no drug dose changed on the basis of this text.
References
- eviQ (Cancer Institute NSW). Acneiform rash (papulopustular rash) associated with EGFR inhibitors. eviq.org.au
- ESMO Oncology in Practice. Reactive management of nail changes induced by multikinase inhibitor treatment. oncologypro.esmo.org
- Sollena P, et al. Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature. Drugs Context. 2019;8:212613. pmc.ncbi.nlm.nih.gov
- OncLive. Experts discuss the management of paronychia when treating patients with EGFR TKIs. onclive.com
- TAGRISSO (osimertinib) prescribing information, adverse reactions, FLAURA. medlibrary.org
- GILOTRIF (afatinib) prescribing information, adverse reactions, LUX-Lung 3. medthority.com
- Johnson & Johnson Medical Connect. Safety information for RYBREVANT dermatologic adverse reactions. jnjmedicalconnect.com
- Johnson & Johnson. Enhanced preventive regimen reduces dermatologic reactions in EGFR-mutated advanced NSCLC (COCOON). jnj.com
- CURE. COCOON trial regimen reduces dermatologic side effects in mutated lung cancer. curetoday.com
- CancerNetwork. Dermatologic management sustains QOL after amivantamab combo in EGFR+ NSCLC. cancernetwork.com
- The ASCO Post. Amivantamab plus lazertinib vs osimertinib in EGFR-mutated advanced NSCLC (MARIPOSA). 2025. ascopost.com
- ILCN. COCOON’s prophylactic regimen resulted in decreased incidence and severity of dermatologic-related adverse events. ilcn.org
Was this article helpful?
Your feedback helps us improve our content.
